These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Prediction of the immediate outcome of femoropopliteal saphenous vein bypass by angiographic runoff score. Albäck A; Biancari F; Saarinen O; Lepäntalo M Eur J Vasc Endovasc Surg; 1998 Mar; 15(3):220-4. PubMed ID: 9587334 [TBL] [Abstract][Full Text] [Related]
44. Preparation for femoropopliteal bypass. A new method to utilize the small saphenous vein. Turcotte JG; Dent TL; Fry WJ Arch Surg; 1970 May; 100(5):627-9. PubMed ID: 5438577 [No Abstract] [Full Text] [Related]
45. Results of bypass to the popliteal and tibial arteries with alternative sources of autogenous vein. Gentile AT; Lee RW; Moneta GL; Taylor LM; Edwards JM; Porter JM J Vasc Surg; 1996 Feb; 23(2):272-9; discussion 279-80. PubMed ID: 8637104 [TBL] [Abstract][Full Text] [Related]
46. Long-term outcome of femoral above-knee popliteal artery bypass using autologous saphenous vein versus expanded polytetrafluoroethylene grafts. Sala F; Hassen-Khodja R; Lecis A; Bouillanne PJ; Declemy S; Batt M Ann Vasc Surg; 2003 Jul; 17(4):401-7. PubMed ID: 14670018 [TBL] [Abstract][Full Text] [Related]
47. Dacron or ePTFE for femoro-popliteal above-knee bypass grafting: short- and long-term results of a multicentre randomised trial. van Det RJ; Vriens BH; van der Palen J; Geelkerken RH Eur J Vasc Endovasc Surg; 2009 Apr; 37(4):457-63. PubMed ID: 19231253 [TBL] [Abstract][Full Text] [Related]
48. Durability of the in situ saphenous vein arterial bypass: a comparison of primary and secondary patency. Bandyk DF; Kaebnick HW; Stewart GW; Towne JB J Vasc Surg; 1987 Feb; 5(2):256-68. PubMed ID: 3546739 [TBL] [Abstract][Full Text] [Related]
49. Assessment of reconstructive procedures for femoropopliteal artery occlusive disease. Downs AR Am Heart J; 1971 May; 81(5):716-7. PubMed ID: 5552074 [No Abstract] [Full Text] [Related]
52. Femoropopliteal bypass with either adequate ipsilateral reversed saphenous vein or obligatory polytetrafluoroethylene. Archie JP Ann Vasc Surg; 1994 Sep; 8(5):475-84. PubMed ID: 7811585 [TBL] [Abstract][Full Text] [Related]
53. Sparks mandril, velour Dacron and autogenous saphenous vein grafts in femoropopliteal bypass. Christenson JT; Eklöf B Br J Surg; 1979 Jul; 66(7):514-7. PubMed ID: 157181 [TBL] [Abstract][Full Text] [Related]
54. Graft type for femoro-popliteal bypass surgery. Twine CP; McLain AD Cochrane Database Syst Rev; 2010 May; (5):CD001487. PubMed ID: 20464717 [TBL] [Abstract][Full Text] [Related]
55. Femoropopliteal bypass grafting for intermittent claudication: is pessimism warranted? Donaldson MC; Mannick JA Arch Surg; 1980 Jun; 115(6):724-7. PubMed ID: 7387359 [TBL] [Abstract][Full Text] [Related]
56. The long-term value of composite grafts for limb salvage. Chang JB; Stein TA J Vasc Surg; 1995 Jul; 22(1):25-31. PubMed ID: 7602709 [TBL] [Abstract][Full Text] [Related]
57. Endarterectomy of the superficial femoral artery: a procedure worth reconsidering. van der Heijden FH; Eikelboom BC; van Reedt Dortland RW; van der Graaf Y; Steijling JJ; Legemate DA; van Vroonhoven TJ Eur J Vasc Surg; 1992 Nov; 6(6):651-8. PubMed ID: 1451824 [TBL] [Abstract][Full Text] [Related]
60. Clinical and anatomic considerations for surgery in femoropopliteal disease and the results of surgery. Taylor LM; Porter JM Circulation; 1991 Feb; 83(2 Suppl):I63-9. PubMed ID: 1991402 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]